TScan Therapeutics (TCRX) announced the appointment of Jason Amello as Chief Financial Officer. Amello, a senior finance executive, brings to TScan nearly three decades of expertise in financial strategy, business development, and operations in the biotechnology industry. Amello joins TScan from Candel Therapeutics (CADL) where he served as the Chief Financial Officer, Treasurer and Secretary, and developed the company’s financial strategy and supported its business development initiatives.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TCRX:
- TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR
- 2 Best Stocks to Buy Now, 1/5/2024, According to Top Analysts
- TScan Therapeutics announces 2024 clinical plans, recent progress
- TScan Therapeutics presents initial Phase 1 results on TSC-100, TSC-101
- TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition
